097456-0003-02931-NY01.2130985.1 06/04/02
2:20 PM
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of June, 2002
GALEN HOLDINGS PUBLIC LIMITED COMPANY
-----------------------------------------------------------------------------
-
(Translation of registrant's name into English)
SEAGOE INDUSTRIAL ESTATE
CRAIGAVON
BT63 5UA
UNITED KINGDOM
-----------------------------------------------------------------------------
-
(Address of principal executive offices)
(Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.)
Form 20-F _X_ Form 40-F___
(Indicate by check mark whether the registrant by furnishing the information
contained in this form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.)
Yes___ No _X_
(If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2(b): 82-_____.
Schedule of Information Contained in this Report
Press releases announcing the declaration of a dividend on May 8, 2002,
results of the extraordinary general meeting on May 29, 2002 and the
completion of the sale of Galen's CTS business to companies controlled by
Allen McClay on May 31, 2002.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
GALEN HOLDINGS PUBLIC LIMITED COMPANY
By: ______
Name:
Title:
Date: June 4, 2002
8 May 2002
Galen Holdings PLC
Dividend Declaration
The Company declares a dividend of 1p. The Dividend payment date is 23
August 2002 and the record date is 26 July 2002.
For further information, please contact:
Galen Holdings
David G. Kelly
Tel: + 44 (0) 28 3833 4974
Financial Dynamics
Fiona Noblet/Sophie Pender-Cudlip
Tel: + 44 (0) 20 7831 3113
NEWS RELEASE
Craigavon, Northern Ireland/Rockaway, NJ 29
May 2002
GALEN HOLDINGS PLC
RESULT OF EXTRAORDINARY GENERAL MEETING
Statement regarding disposal of CTS
Craigavon, Northern Ireland, UK / Rockaway, New Jersey, USA. 29 May 2002 ..
The Board of Galen Holdings PLC (LSE: GAL, Nasdaq: GALN), is pleased to
announce that at today's Extraordinary General Meeting of the Company, the
Ordinary Resolution in respect of the proposed disposal of the Clinical
Trial Services Business, as detailed in the circular sent to shareholders
on 8 May 2002, was approved by shareholders. Accordingly, completion is
expected to occur on 31 May 2002 subject to approval from competition
authorities.
Commenting on the result of the vote, John King, Executive Chairman of
Galen commented, "We are pleased to complete this important step in our
transition to a pharma focused company. Our key promoted products show
continued success in the marketplace and are exhibiting strong growth. This
growth, supported by a strong pipeline with two NDA's filed and one more
due for filing early next year, augers well for continued success. Our best
wishes for the future go to all our colleagues in CTS."
Galen is an integrated specialty pharmaceutical company based in Craigavon,
Northern Ireland and Rockaway, New Jersey, USA. Galen develops, acquires
and manufactures branded prescription pharmaceutical products, which are
promoted by the company's sales and marketing organizations in the UK,
Ireland and the US.
###
For further information please contact:
GALEN
David G. Kelly,
Senior Vice President, Finance and Planning
Telephone: +44 (0) 28 3833 4974
CREDIT SUISSE FIRST BOSTON
Andrew Christie
Telephone: +44 (0) 207 888 8888
FINANCIAL DYNAMICS
Fiona Noblet / Sophie Pender-Cudlip
Telephone: +44 (0) 20 7831 3113
For further information on Galen, please visit www.galenplc.com
Note: Forward looking statements in this report, including, without
limitation, statements relating to Galen's plans, strategies, objectives,
expectations, intentions and adequacy of resources, are made pursuant to
the safe harbor provisions of the U.S. Private Securities Litigation Reform
Act of 1995. These forward looking statements involve known and unknown
risks, uncertainties and other factors that may cause the actual results,
performance or achievements of Galen to be materially different from any
future results, performance or achievements expressed or implied by such
forward looking statements. These factors include, among others, the
following: Galen's ability to manage its growth, government regulation
affecting the development, manufacture, marketing and sale of
pharmaceutical products, customer acceptance of new products, competitive
factors in the industries in which Galen operates, the loss of key senior
management or scientific staff, exchange rate fluctuations, general
economic and business conditions, and other factors described in filings of
Galen with the SEC. Galen undertakes no obligation to publicly update or
revise any forward looking statement, whether as a result of new
information, future events or otherwise.
For Immediate Release 31 May 2002
Galen Holdings PLC
Statement regarding disposal of CTS
GALEN HOLDINGS PLC ("GALEN")
COMPLETION OF CLINICAL TRIAL SERVICES DISPOSAL ("CTS")
31 May 2002
Following the expiry of the waiting period under the Hart-Scott-Rodino
Antitrust Improvements Act of 1976, the Board of Galen is pleased to
announce that it has completed the disposal of the Clinical Trial Services
Business, as detailed in the circular sent to shareholders on 8 May 2002.